ESP

Espey is a genuinely improved business. Revenue has compounded from $27.7M (FY2021) to $44.0M (FY2025), and net income swung from a -$182K loss to $8.14M (+40% YoY) over the same span, with diluted EPS up 31.9% to $3.02. The balance sheet is fortress-like for a microcap: $18.9M cash (up 333%), $50.8M equity against just $28.3M liabilities (0.56x), and $21.0M operating cash flow (+98%) that easily funds the $2.6M dividend and modest sub-$850K FY2026 capex plan. ROE of 16% and an 18.5% operating margin round out a high-quality, cash-generative defense/power-electronics supplier riding real end-market demand — the MD&A notes power-electronics shortages and component lead times approaching a year, evidence of a tight supply environment that favors incumbents with long prime-contractor relationships.

The problem is the forward setup, and management says so plainly. The FY2025 10-K guides that while FY2026 revenue should be higher, 'net income per share is anticipated to fall below fiscal 2025 results' because backlog orders shipping in FY2026 carry 'higher anticipated aggregate costs' than the FY2025 mix. That is an explicit margin-compression and EPS-decline warning on an already-thin 28.9% gross margin. Management also expects FY2026 new orders to come in below the $86.4M booked in FY2025 — a figure inflated by two multi-year awards totaling $49.4M — so the comparison gets tougher on both margin and bookings. Paying 21.5x trailing EPS and 4.3x sales for a business whose own management is guiding next-year EPS lower is a full price, not a bargain.